Orforglipron led to 11.5% placebo-adjusted weight loss at 72 weeks (among those who adhered to high-dose treatment) in Attain-1, versus 13.9% at 64 weeks in Oasis 4 for the 25-mg dose of oral ...

Security researchers found two techniques to crack at least eight brands of electronic safes—used to secure everything from ...

Indianapolis-based Eli Lilly and Co. shares fell Thursday, Aug. 7 following the pharmaceutical company's second-quarter ...

As drug companies increasingly adopt the DTC sales model, patients will gain the ability to buy the medicines they need at ...

The growing healthcare burden posed by hepatocellular carcinoma, the most common subtype of liver cancer, has prompted the ...

Ladies and gentlemen, thank you for standing by, and welcome to the Lilly Q2 2025 Earnings Conference Call. [Operator ...

Lilly’s results from an obesity pill study didn’t perform as well as Wall Street expected. It resulted in lower weight loss ...

Eli Lilly & Co. tumbled as disappointing data on its new weight-loss pill overshadowed strong growth from the company’s current obesity medicine, which helped drive it to raise its yearly profit and ...

Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) fell 13.9% in the afternoon session after its oral weight-loss ...

Eli Lilly reports strong Q2 2025 growth, driven by Mounjaro & Zepbound. Highlights include increased guidance, pipeline updates, and key clinical milestones.

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.